| Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569] | Technology appraisal guidance |
| Pre-operative and post-operative rehabilitation digital tools (and med-tech) for patients undergoing hip or knee surgery | Health technology evaluation |
| Prevention of dementia | Quality standard |
| Primary hyperparathyroidism | Quality standard |
| Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127] | Technology appraisal guidance |
| PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130] | Technology appraisal guidance |
| Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512] | Technology appraisal guidance |
| Ranibizumab port delivery system for treating diabetic macular oedema [ID6137] | Technology appraisal guidance |
| Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319] | Technology appraisal guidance |
| Readmission to ICU within 48hrs | Quality standard |
| REGN5458 for treating relapsed or refractory multiple myeloma [TSID10443] | Technology appraisal guidance |
| Remdesivir for treating COVID 19 [ID3808] | Technology appraisal guidance |
| Remibrutinib for treating chronic spontaneous urticaria
inadequately controlled by H1-antihistamines [ID6356] | Technology appraisal guidance |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529] | Technology appraisal guidance |
| Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome [ID6478] | Technology appraisal guidance |
| Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436] | Technology appraisal guidance |
| Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy
[ID6482] | Technology appraisal guidance |
| Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395] | Technology appraisal guidance |
| Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584] | Technology appraisal guidance |
| Rivaroxaban for treating chronic heart failure [ID1462] | Technology appraisal guidance |
| Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819] | Technology appraisal guidance |
| Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565] | Technology appraisal guidance |
| Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764] | Technology appraisal guidance |
| Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763] | Technology appraisal guidance |
| Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410] | Technology appraisal guidance |
| Sabizabulin for treating COVID 19 [TSID11814] | Technology appraisal guidance |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID12198] | Technology appraisal guidance |
| Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433] | Technology appraisal guidance |
| Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal | Quality standard |
| Safeguarding adults in care homes | Quality standard |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [TSID10237] | Technology appraisal guidance |
| Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506] | Technology appraisal guidance |
| Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454] | Technology appraisal guidance |
| Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520] | Technology appraisal guidance |
| Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib
[ID6494] | Technology appraisal guidance |
| Secondary care management of malignant hypertension | Quality standard |
| Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163] | Technology appraisal guidance |
| Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825] | Technology appraisal guidance |
| Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385] | Technology appraisal guidance |
| Semaglutide for treating type 2 diabetes [ID1450] | Technology appraisal guidance |
| Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older
[ID6542] | Technology appraisal guidance |
| Shared decision-making: practical guidance for health and social care professionals | Quality standard |
| Sibeprenlimab for treating IgA nephropathy [TSID12111] | Technology appraisal guidance |
| Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147] | Technology appraisal guidance |
| Sleep disordered breathing | Quality standard |
| Social work interventions for adults with complex needs (including learning disabilities) and mental health needs | Quality standard |
| Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536] | Technology appraisal guidance |
| Sotagliflozin for treating type 2 diabetes [ID1657] | Technology appraisal guidance |
| Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955] | Technology appraisal guidance |
| Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions | Medical technologies guidance |